Top Story
October 4, 2019
Read the
Perspective
from
James A. McKinnell, MD
WASHINGTON — Cefiderocol, a novel siderophore cephalosporin, was noninferior to high-dose meropenem for the primary endpoint of all-cause mortality 14 days after treatment was started in patients with nosocomial pneumonia caused by gram-negative pathogens, according to results of a randomized phase 3 trial called APEKS-NP.
“Data from APEKS-NP provide meaningful evidence that cefiderocol has the potential to be an effective treatment option for severely ill hospitalized patients with pneumonia,” Tsutae “Den” Nagata, MD, PhD, FFPM, chief medical officer at Shionogi, said in a press release.
In the Journals
September 24, 2019
Among patients with acute respiratory distress syndrome, shorter women were less likely to receive lower tidal volume ventilation and women with severe confirmed disease…
Editorial
September 3, 2019
For people in the realm of acute respiratory distress syndrome research, the LIVE trial, conducted by Constantin and colleagues and published in The Lancet Respiratory…
In the Journals
August 30, 2019
In patients with acute respiratory distress syndrome, personalizing mechanical ventilation based on lung morphology did not decrease mortality at 90 days, according to…